{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T01:31:41Z","timestamp":1710984701620},"reference-count":74,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"DOI":"10.7759\/cureus.56545","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T13:46:49Z","timestamp":1710942409000},"source":"Crossref","is-referenced-by-count":0,"title":["Current Progress on the Influence Human Genetics Has on the Efficacy of Tyrosine Kinase Inhibitors Used to Treat Chronic Myeloid Leukemia"],"prefix":"10.7759","author":[{"given":"Tara C","family":"Prakash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Enkemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian X","year":"2018","unstructured":"Tian X, Zhang H, Heimbach T, He H, Buchbinder A, Aghoghovbia M, Hourcade-Potelleret F. Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor. J Clin Pharmacol. 2018, 58:1533-40. 10.1002\/jcph.1312","journal-title":"J Clin Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","volume":"477","author":"Kumar V","year":"2022","unstructured":"Kumar V, Singh P, Gupta SK, Ali V, Verma M. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem. 2022, 477:1261-79. 10.1007\/s11010-022-04376-6","journal-title":"Mol Cell Biochem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.219","article-title":"Defining and managing imatinib resistance","author":"Mauro MJ","year":"2006","unstructured":"Mauro MJ. Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program. 2006, 219-25. 10.1182\/asheducation-2006.1.219","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","unstructured":"Chronic myeloid leukemia. (2023). Accessed. January 13, 2024: https:\/\/emedicine.medscape.com\/article\/199425-overview."},{"key":"ref5","unstructured":"Cancer Stat Facts. Leukemia \u2014 chronic myeloid leukemia (CML). (2023). Accessed: January 13, 2024: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang Y","year":"2022","unstructured":"Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022, 7:329. 10.1038\/s41392-022-01168-8","journal-title":"Signal Transduct Target Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0082-x","article-title":"Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"28","author":"Syed YY","year":"2014","unstructured":"Syed YY, McCormack PL, Plosker GL. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. BioDrugs. 2014, 28:107-20. 10.1007\/s40259-013-0082-x","journal-title":"BioDrugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1276","article-title":"The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL","volume":"72","author":"Hantschel O","year":"2012","unstructured":"Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012, 72:4890-5. 10.1158\/0008-5472.CAN-12-1276","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann JL","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012, 53:2351-61. 10.3109\/10428194.2012.695779","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4065\/84.2.161","article-title":"Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?","volume":"84","author":"Jabbour E","year":"2009","unstructured":"Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. Mayo Clin Proc. 2009, 84:161-9. 10.4065\/84.2.161","journal-title":"Mayo Clin Proc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace F","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, et al.. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011, 118:4554-60. 10.1182\/blood-2011-04-347575","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03432-7","article-title":"Asciminib as a third line option in chronic myeloid leukemia","volume":"117","author":"Lagan\u00e0 A","year":"2023","unstructured":"Lagan\u00e0 A, Scalzulli E, Carmosino I, Martelli M, Breccia M. Asciminib as a third line option in chronic myeloid leukemia. Int J Hematol. 2023, 117:16-23. 10.1007\/s12185-022-03432-7","journal-title":"Int J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini S","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, et al.. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006, 12:7374-9. 10.1158\/1078-0432.CCR-06-1516","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare T","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007, 110:2242-9. 10.1182\/blood-2007-03-066936","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford S","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood. 2009, 114:5426-35. 10.1182\/blood-2009-08-215939","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000210060","article-title":"BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors","volume":"121","author":"Ma W","year":"2009","unstructured":"Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009, 121:27-31. 10.1159\/000210060","journal-title":"Acta Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini S","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, et al.. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014, 38:10-20. 10.1016\/j.leukres.2013.09.011","journal-title":"Leuk Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-017-0292-x","article-title":"Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia","volume":"21","author":"Nath A","year":"2017","unstructured":"Nath A, Wang J, Stephanie Huang R. Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol Diagn Ther. 2017, 21:621-31. 10.1007\/s40291-017-0292-x","journal-title":"Mol Diagn Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.02.005","article-title":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"131","author":"Cargnin S","year":"2018","unstructured":"Cargnin S, Ravegnini G, Soverini S, Angelini S, Terrazzino S. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis. Pharmacol Res. 2018, 131:244-54. 10.1016\/j.phrs.2018.02.005","journal-title":"Pharmacol Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/164_2023_639","article-title":"Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"280","author":"Kaehler M","year":"2023","unstructured":"Kaehler M, Cascorbi I. Molecular mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Handb Exp Pharmacol. 2023, 280:65-83. 10.1007\/164_2023_639","journal-title":"Handb Exp Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger MW","year":"2003","unstructured":"Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003, 55:401-23. 10.1124\/pr.55.3.4","journal-title":"Pharmacol Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener C","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F, Ferrero A, Saglio G, Pravettoni G, Sant M. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020, 4:2723-35. 10.1182\/bloodadvances.2019001329","journal-title":"Blood Adv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.09.08","article-title":"Role of pharmacogenetics in personalized imatinib dosing","volume":"6","author":"Barratt D","year":"2017","unstructured":"Barratt D, Somogyi A. Role of pharmacogenetics in personalized imatinib dosing. Transl Cancer Res. 2017, 6:1541-57. 10.21037\/tcr.2017.09.08","journal-title":"Transl Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0494-0","article-title":"CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients","volume":"56","author":"Barratt DT","year":"2017","unstructured":"Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA. CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clin Pharmacokinet. 2017, 56:977-85. 10.1007\/s40262-016-0494-0","journal-title":"Clin Pharmacokinet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/srep17778","article-title":"Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases","volume":"5","author":"Zhang N","year":"2015","unstructured":"Zhang N, Liu Y, Jeong H. Drug-drug interaction potentials of tyrosine kinase inhibitors via inhibition of UDP-glucuronosyltransferases. Sci Rep. 2015, 5:17778. 10.1038\/srep17778","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula AM","year":"2013","unstructured":"Filppula AM, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. 2013, 41:50-9. 10.1124\/dmd.112.048017","journal-title":"Drug Metab Dispos"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama A","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009, 16:122-31. 10.1177\/107327480901600204","journal-title":"Cancer Control"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1999","article-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","volume":"20","author":"Nies AT","year":"2014","unstructured":"Nies AT, Schaeffeler E, van der Kuip H, et al.. Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res. 2014, 20:985-94. 10.1158\/1078-0432.CCR-13-1999","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/srep29559","article-title":"Impact of ABCB1 1236C\u2009>\u2009T-2677G\u2009>\u2009T-3435C\u2009>\u2009T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib","volume":"6","author":"Dessilly G","year":"2016","unstructured":"Dessilly G, Panin N, Elens L, Haufroid V, Demoulin JB. Impact of ABCB1 1236C\u2009>\u2009T-2677G\u2009>\u2009T-3435C\u2009>\u2009T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Sci Rep. 2016, 6:29559. 10.1038\/srep29559","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au A","year":"2014","unstructured":"Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother. 2014, 68:343-9. 10.1016\/j.biopha.2014.01.009","journal-title":"Biomed Pharmacother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1876661","article-title":"ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?","volume":"17","author":"Bruckmueller H","year":"2021","unstructured":"Bruckmueller H, Cascorbi I. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?. Expert Opin Drug Metab Toxicol. 2021, 17:369-96. 10.1080\/17425255.2021.1876661","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim DH","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, et al.. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009, 15:4750-8. 10.1158\/1078-0432.CCR-09-0145","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2035-3","article-title":"Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?","volume":"71","author":"Gandia P","year":"2013","unstructured":"Gandia P, Arellano C, Lafont T, Huguet F, Malard L, Chatelut E. Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?. Cancer Chemother Pharmacol. 2013, 71:531-6. 10.1007\/s00280-012-2035-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain A","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, et al.. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res. 2008, 14:7102-9. 10.1158\/1078-0432.CCR-08-0950","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.5772\/56101","article-title":"Molecular aspects of human alpha-1 acid glycoprotein \u2014 structure and function","author":"Taguchi K","year":"2013","unstructured":"Taguchi K, Nishi K., Giam Chuang VT, Maruyam T, Otagiri M. Molecular aspects of human alpha-1 acid glycoprotein \u2014 structure and function. Acute Phase Proteins. Janciauskiene S (ed): InTech, Hanover, Germany; 2013. 10.5772\/56101"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020330","article-title":"Impact of variants in the ATIC and ARID5B genes on therapeutic failure with imatinib in patients with chronic myeloid leukemia","volume":"13","author":"Cereja Pantoja KB","year":"2022","unstructured":"Cereja Pantoja KB, Azevedo TC, Carvalho DC, et al.. Impact of variants in the ATIC and ARID5B genes on therapeutic failure with imatinib in patients with chronic myeloid leukemia. Genes (Basel). 2022, 13:330. 10.3390\/genes13020330","journal-title":"Genes (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac101","article-title":"Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia","volume":"114","author":"Zhao X","year":"2022","unstructured":"Zhao X, Qian M, Goodings C, et al.. Molecular mechanisms of ARID5B-mediated genetic susceptibility to acute lymphoblastic leukemia. J Natl Cancer Inst. 2022, 114:1287-95. 10.1093\/jnci\/djac101","journal-title":"J Natl Cancer Inst"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2021.547","article-title":"The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review","volume":"15","author":"Prenggono MD","year":"2021","unstructured":"Prenggono MD, Yasmina A, Ariyah M, Wanahari TA, Hasrianti N. The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review. Oncol Rev. 2021, 15:547. 10.4081\/oncol.2021.547","journal-title":"Oncol Rev"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.61615","article-title":"Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy","volume":"182","author":"Wenger TL","year":"2020","unstructured":"Wenger TL, Bly RA, Wu N, et al.. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020, 182:1576-91. 10.1002\/ajmg.a.61615","journal-title":"Am J Med Genet A"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2006.08.002","article-title":"Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice","volume":"72","author":"Nakagawa H","year":"2006","unstructured":"Nakagawa H, Takiguchi T, Nakamura M, et al.. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. Biochem Pharmacol. 2006, 72:1237-45. 10.1016\/j.bcp.2006.08.002","journal-title":"Biochem Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.115","article-title":"Novel approaches to therapy in CML","volume":"2017","author":"Bhatia R","year":"2017","unstructured":"Bhatia R. Novel approaches to therapy in CML. Hematology Am Soc Hematol Educ Program. 2017, 2017:115-20. 10.1182\/asheducation-2017.1.115","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","author":"Talati C","year":"2018","unstructured":"Talati C, Pinilla-Ibarz J. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents. Curr Opin Hematol. 2018, 25:154-61. 10.1097\/MOH.0000000000000403","journal-title":"Curr Opin Hematol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0175","article-title":"Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment","volume":"7","author":"Arrigoni E","year":"2018","unstructured":"Arrigoni E, Del Re M, Galimberti S, et al.. Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. Stem Cells Transl Med. 2018, 7:305-14. 10.1002\/sctm.17-0175","journal-title":"Stem Cells Transl Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun TP","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020, 37:530-42. 10.1016\/j.ccell.2020.03.006","journal-title":"Cancer Cell"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.01.016","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","volume":"38 Suppl 1","author":"Blay JY","year":"2011","unstructured":"Blay JY, von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011, 38 Suppl 1:S3-9. 10.1053\/j.seminoncol.2011.01.016","journal-title":"Semin Oncol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2022.06.001","article-title":"Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis","volume":"365","author":"Cui X","year":"2022","unstructured":"Cui X, Sun J, Li C, Qiu S, Shi C, Ma J, Xu Y. Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022, 365:11-23. 10.1016\/j.toxlet.2022.06.001","journal-title":"Toxicol Lett"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15911","article-title":"The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis","volume":"179","author":"Carracedo M","year":"2022","unstructured":"Carracedo M, Pawelzik SC, Artiach G, et al.. The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis. Br J Pharmacol. 2022, 179:4709-21. 10.1111\/bph.15911","journal-title":"Br J Pharmacol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.966182","article-title":"Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis","volume":"9","author":"Li S","year":"2022","unstructured":"Li S, He J, Zhang X, Cai Y, Liu J, Nie X, Shi L. Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis. Front Cardiovasc Med. 2022, 9:966182. 10.3389\/fcvm.2022.966182","journal-title":"Front Cardiovasc Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya M","year":"2014","unstructured":"Abumiya M, Takahashi N, Niioka T, et al.. Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia. Drug Metab Pharmacokinet. 2014, 29:449-54. 10.2133\/dmpk.DMPK-14-RG-031","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0562-5","article-title":"Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia","volume":"19","author":"Shibata T","year":"2014","unstructured":"Shibata T, Minami Y, Mitsuma A, et al.. Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Int J Clin Oncol. 2014, 19:391-6. 10.1007\/s10147-013-0562-5","journal-title":"Int J Clin Oncol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.5538.5538","article-title":"Polymorphism of UGT1A1 and frequency of hyperbilirubinemia in patients with chronic myeloid leukemia treated by nilotinib","volume":"124","author":"Bykova A","year":"2014","unstructured":"Bykova A, Abdullayev AO, Gusarova G, Chelysheva E, Treglazova S, Smirnova S, Turkina A. Polymorphism of UGT1A1 and frequency of hyperbilirubinemia in patients with chronic myeloid leukemia treated by nilotinib. Blood. 2014, 124:5538. 10.1182\/blood.V124.21.5538.5538","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie LN","year":"2014","unstructured":"Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clin Pharmacol Ther. 2014, 95:294-306. 10.1038\/clpt.2013.208","journal-title":"Clin Pharmacol Ther"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21406","article-title":"The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia","volume":"8","author":"Galimberti S","year":"2017","unstructured":"Galimberti S, Bucelli C, Arrigoni E, et al.. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget. 2017, 8:88021-33. 10.18632\/oncotarget.21406","journal-title":"Oncotarget"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2016-0012","article-title":"ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib","volume":"17","author":"Dessilly G","year":"2016","unstructured":"Dessilly G, Elens L, Panin N, Karmani L, Demoulin JB, Haufroid V. ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics. 2016, 17:883-90. 10.2217\/pgs-2016-0012","journal-title":"Pharmacogenomics"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.07.009","article-title":"Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models","volume":"311","author":"Hebron M","year":"2017","unstructured":"Hebron M, Peyton M, Liu X, Gao X, Wang R, Lonskaya I, Moussa CE. Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models. J Neuroimmunol. 2017, 311:1-9. 10.1016\/j.jneuroim.2017.07.009","journal-title":"J Neuroimmunol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson's disease","volume":"7","author":"Pagan FL","year":"2019","unstructured":"Pagan FL, Hebron ML, Wilmarth B, et al.. Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson's disease. Pharmacol Res Perspect. 2019, 7:e00470. 10.1002\/prp2.470","journal-title":"Pharmacol Res Perspect"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.5045\/br.2021.2021117","article-title":"A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities","volume":"56","author":"Nekoukar Z","year":"2021","unstructured":"Nekoukar Z, Moghimi M, Salehifar E. A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. Blood Res. 2021, 56:229-42. 10.5045\/br.2021.2021117","journal-title":"Blood Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia","volume":"9","author":"Chen R","year":"2015","unstructured":"Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther. 2015, 9:773-9. 10.2147\/DDDT.S80207","journal-title":"Drug Des Devel Ther"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019865704","article-title":"Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors","volume":"9","author":"El-Dabh A","year":"2019","unstructured":"El-Dabh A, Acharya D. Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors. Pulm Circ. 2019, 9:2045894019865704. 10.1177\/2045894019865704","journal-title":"Pulm Circ"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.s.001","article-title":"Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective","volume":"10","author":"Jabbour E","year":"2010","unstructured":"Jabbour E, Fullmer A, Cort\u00e9s JE, Kantarjian H. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective. Clin Lymphoma Myeloma Leuk. 2010, 10:S6-13. 10.3816\/CLML.2010.s.001","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans","volume":"36","author":"Christopher LJ","year":"2008","unstructured":"Christopher LJ, Cui D, Wu C, et al.. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008, 36:1357-64. 10.1124\/dmd.107.018267","journal-title":"Drug Metab Dispos"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics","volume":"12","author":"He S","year":"2021","unstructured":"He S, Bian J, Shao Q, et al.. Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics. Front Pharmacol. 2021, 12:797881. 10.3389\/fphar.2021.797881","journal-title":"Front Pharmacol"},{"key":"ref63","article-title":"Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy","volume":"1","author":"Xu Z","year":"2009","unstructured":"Xu Z, Cang S, Yang T, Liu D. Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy. Hematol Rev. 2009, 1:e4.","journal-title":"Hematol Rev"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert C","year":"2016","unstructured":"Guignabert C, Phan C, Seferian A, et al.. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016, 126:3207-18. 10.1172\/JCI86249","journal-title":"J Clin Invest"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.063172","article-title":"Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis","volume":"98","author":"Gurion R","year":"2013","unstructured":"Gurion R, Gafter-Gvili A, Vidal L, et al.. Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. Haematologica. 2013, 98:95-102. 10.3324\/haematol.2012.063172","journal-title":"Haematologica"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2013.4.6.8","article-title":"Bosutinib: a novel src\/abl kinase inhibitor for chronic myelogenous leukemia","volume":"4","author":"Steinbach A","year":"2013","unstructured":"Steinbach A, Clark SM, Clemmons AB. Bosutinib: a novel src\/abl kinase inhibitor for chronic myelogenous leukemia. J Adv Pract Oncol. 2013, 4:451-5. 10.6004\/jadpro.2013.4.6.8","journal-title":"J Adv Pract Oncol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes JE","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH, et al.. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011, 118:4567-76. 10.1182\/blood-2011-05-355594","journal-title":"Blood"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini C","year":"2014","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, et al.. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014, 89:947-53. 10.1002\/ajh.23788","journal-title":"Am J Hematol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S30182","article-title":"Bosutinib in the management of chronic myelogenous leukemia","volume":"7","author":"Amsberg GK","year":"2013","unstructured":"Amsberg GK, Schafhausen P. Bosutinib in the management of chronic myelogenous leukemia. Biologics. 2013, 7:115-22. 10.2147\/BTT.S30182","journal-title":"Biologics"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111905","article-title":"Pharmacokinetic and pharmacogenetic analysis of bosutinib in japanese patients with chronic-phase chronic myeloid leukemia","volume":"132","author":"Mita A","year":"2018","unstructured":"Mita A, Abumiya M, Takahashi S, Kameoka Y, Miura M, Takahashi N. Pharmacokinetic and pharmacogenetic analysis of bosutinib in japanese patients with chronic-phase chronic myeloid leukemia. Blood. 2018, 132:4271. 10.1182\/blood-2018-99-111905","journal-title":"Blood"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0555","article-title":"The role of bosutinib in the treatment of chronic myeloid leukemia","volume":"16","author":"Gambacorti-Passerini C","year":"2020","unstructured":"Gambacorti-Passerini C, le Coutre P, Piazza R. The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncol. 2020, 16:4395-408. 10.2217\/fon-2019-0555","journal-title":"Future Oncol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17548","article-title":"Inhibition of soluble epoxide hydrolase attenuates bosutinib-induced blood pressure elevation","volume":"78","author":"Cui Z","year":"2021","unstructured":"Cui Z, Li B, Zhang Y, et al.. Inhibition of soluble epoxide hydrolase attenuates bosutinib-induced blood pressure elevation. Hypertension. 2021, 78:1527-40. 10.1161\/HYPERTENSIONAHA.121.17548","journal-title":"Hypertension"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2161","article-title":"Opportunity for genotype-guided prescribing among adult patients in 11 US health systems","volume":"110","author":"Hicks JK","year":"2021","unstructured":"Hicks JK, El Rouby N, Ong HH, et al.. Opportunity for genotype-guided prescribing among adult patients in 11 US health systems. Clin Pharmacol Ther. 2021, 110:179-88. 10.1002\/cpt.2161","journal-title":"Clin Pharmacol Ther"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2000.11927719","article-title":"Drug interactions due to cytochrome P450","volume":"13","author":"Ogu CC","year":"2000","unstructured":"Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent). 2000, 13:421-3. 10.1080\/08998280.2000.11927719","journal-title":"Proc (Bayl Univ Med Cent)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/226818-current-progress-on-the-influence-human-genetics-has-on-the-efficacy-of-tyrosine-kinase-inhibitors-used-to-treat-chronic-myeloid-leukemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T13:46:54Z","timestamp":1710942414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/226818-current-progress-on-the-influence-human-genetics-has-on-the-efficacy-of-tyrosine-kinase-inhibitors-used-to-treat-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":74,"URL":"https:\/\/doi.org\/10.7759\/cureus.56545","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}